These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26235208)

  • 1. Comparison of Glioblastomas and Brain Metastases using Dynamic Contrast-Enhanced Perfusion MRI.
    Jung BC; Arevalo-Perez J; Lyo JK; Holodny AI; Karimi S; Young RJ; Peck KK
    J Neuroimaging; 2016; 26(2):240-6. PubMed ID: 26235208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation between glioblastomas and brain metastases and regarding their primary site of malignancy using dynamic susceptibility contrast MRI at 3T.
    Askaner K; Rydelius A; Engelholm S; Knutsson L; Lätt J; Abul-Kasim K; Sundgren PC
    J Neuroradiol; 2019 Nov; 46(6):367-372. PubMed ID: 30389510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-related Perfusion Changes in White Matter Adjacent to Brain Tumors: Pharmacodynamic Analysis of Dynamic 3T Magnetic Resonance Imaging.
    Tupý R; Mírka H; Mraček J; Přibáň V; Hes O; Vokurka S; Ferda J
    Anticancer Res; 2018 Jul; 38(7):4149-4152. PubMed ID: 29970543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature.
    Jia ZZ; Shi W; Shi JL; Shen DD; Gu HM; Zhou XJ
    Eur J Radiol; 2017 Feb; 87():120-124. PubMed ID: 28034567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
    Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
    Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic contrast-enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases.
    Hatzoglou V; Tisnado J; Mehta A; Peck KK; Daras M; Omuro AM; Beal K; Holodny AI
    Cancer Med; 2017 Apr; 6(4):761-767. PubMed ID: 28303695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
    Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
    Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
    Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
    World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation between glioblastoma, brain metastasis and subtypes using radiomics analysis.
    Artzi M; Bressler I; Ben Bashat D
    J Magn Reson Imaging; 2019 Aug; 50(2):519-528. PubMed ID: 30635952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
    Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
    J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.
    Puig J; Blasco G; Daunis-I-Estadella J; Alberich-Bayarri A; Essig M; Jain R; Remollo S; Hernández D; Puigdemont M; Sánchez-González J; Mateu G; Wintermark M; Pedraza S
    Neuroradiology; 2016 Jan; 58(1):17-26. PubMed ID: 26438560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
    Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.
    Kuchcinski G; Le Rhun E; Cortot AB; Drumez E; Duhal R; Lalisse M; Dumont J; Lopes R; Pruvo JP; Leclerc X; Delmaire C
    Eur Radiol; 2017 Sep; 27(9):3733-3743. PubMed ID: 28210799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
    Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
    Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of brain abscesses from glioblastomas and metastatic brain tumors: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging before and after mathematic contrast leakage correction.
    Toh CH; Wei KC; Chang CN; Ng SH; Wong HF; Lin CP
    PLoS One; 2014; 9(10):e109172. PubMed ID: 25330386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of Primary Brain Tumors and Metastases with Fast Quantitative 3-Dimensional Magnetization Transfer.
    Garcia M; Gloor M; Bieri O; Radue EW; Lieb JM; Cordier D; Stippich C
    J Neuroimaging; 2015; 25(6):1007-14. PubMed ID: 25702714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
    Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.